Mga Batayang Estadistika
| CIK | 1633932 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ESSA Pharma Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission F |
|
| August 25, 2025 |
Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution Exhibit 99.1 Essa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash Distribution SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 25, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) announced on August 14, 2025 that, in connection with the Company’s previously announced return of capital distribution in the aggregate amount of US$80,000,000 (the “D |
|
| August 14, 2025 |
Exhibit 99.1 Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 14, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with the Company’s recently announced return of capital distribution in the aggregate amount of US$80,000,000 ( |
|
| August 14, 2025 |
Exhibit 99.1 Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 14, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with the Company’s recently announced return of capital distribution in the aggregate amount of US$80,000,000 ( |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission F |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-3 |
|
| August 11, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| August 6, 2025 |
Essa Pharma Inc. Announces US$80 million Cash Distribution to Shareholders Exhibit 99.1 Essa Pharma Inc. Announces US$80 million Cash Distribution to Shareholders SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 6, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, following the Company’s receipt of an order from the Supreme Court of British Columbia (the “Court”) on August 5, 2025, authorizing a reduction in the capital of the |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fi |
|
| August 6, 2025 |
Press Release, dated August 6, 2025 Exhibit 99.1 Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 6, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, following the Company’s receipt of an order from the Supreme Court of British Columbia (the “Court”) on August 5, 2025, authorizing a reduction in the capital of the |
|
| July 31, 2025 |
Exhibit 99.1 LETTER TO SHAREHOLDERS OF ESSA PHARMA INC. ESSA Pharma Inc. Suite 720, 999 West Broadway Vancouver, BC V5Z 1K5 Dear Shareholder: As previously announced, on July 13, 2025, ESSA Pharma Inc. (the “Company”), entered into a Business Combination Agreement (the “Agreement”) with XenoTherapeutics, Inc., Xeno Acquisition Corp., a wholly-owned subsidiary of Xeno (“Purchaser”) and XOMA Royalty |
|
| July 31, 2025 |
Letter to Shareholders, dated July 31, 2025 Exhibit 99.1 LETTER TO SHAREHOLDERS OF ESSA PHARMA INC. ESSA Pharma Inc. Suite 720, 999 West Broadway Vancouver, BC V5Z 1K5 Dear Shareholder: As previously announced, on July 13, 2025, ESSA Pharma Inc. (the “Company”), entered into a Business Combination Agreement (the “Agreement”) with XenoTherapeutics, Inc., Xeno Acquisition Corp., a wholly-owned subsidiary of Xeno (“Purchaser”) and XOMA Royalty |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| July 30, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) ESSA Pharma Inc. |
|
| July 30, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| July 23, 2025 |
Exhibit 99.1 ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, July 23, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with its previously announced business combination agreement wit |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| July 14, 2025 |
Exhibit 2.1 BUSINESS COMBINATION AGREEMENT between XenoTherapeutics, Inc. – and – Xeno Acquisition CORP. – and – ESSA PHARMA INC. – and – solely for purposes of Section 10.16, XOMA Royalty Corporation July 13, 2025 TABLE OF CONTENTS Page Article 1 INTERPRETATION 2 1.1 Definitions 2 1.2 Construction and Interpretation 17 1.3 Knowledge 18 1.4 Currency 18 1.5 Accounting Principles 19 1.6 Disclosure i |
|
| July 14, 2025 |
Exhibit 99.1 ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction SOUTH SAN FRANCISCO, CA, VANCOUVER, BC, Boston, Ma, and EMERYVILLE, CA, July 14, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the “Business Combination |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitiv |
|
| July 14, 2025 |
Exhibit 10.1 FORM OF D&O VOTING AND SUPPORT AGREEMENT July 13, 2025 XENO ACQUISITION CORP 923 Elm Street #72, Manchester, NH 03101 Dear Sirs/Madams: Re: Voting and Support Agreement The undersigned understands that Xeno Acquisition Corp. (the “Purchaser”), XenoTherapeutics, Inc., ESSA Pharma Inc. (the “Company”) and, solely for purposes of Section 10.16 thereof, XOMA Royalty Corporation wish to en |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2025 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001- |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————————— FORM 8-K ————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 ————————— ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ————————— British Columbia, Canada (State or other jurisdiction of in |
|
| May 8, 2025 |
Exhibit 99.1 ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025 Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 8, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————————— FORM 8-K ————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2025 ————————— ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ————————— British Columbia, Canada (State or other jurisdiction of |
|
| February 11, 2025 |
EX-99.A 2 ea022754007ex99-aessa.htm JOINT FILING AGREEMENT EXHIBIT 99.A EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Special Opportunities Fund, L.P., a Delaware limited partnership, Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, Soleus Ca |
|
| February 11, 2025 |
Exhibit 99.1 ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024 Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clin |
|
| February 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————————— FORM 8-K ————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2025 ————————— ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ————————— British Columbia, Canada (State or other jurisdiction |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 0 |
|
| January 22, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| December 17, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-37410 ESSA Pharma Inc. |
|
| December 17, 2024 |
EX-99.1 2 ex991.htm PRESS RELEASE DATED DECEMBER 17, 2024 Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024 Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 - ESSA Pharma Inc. ( |
|
| December 17, 2024 |
ESSA Pharma Inc. Disclosure and Insider Trading Policy Exhibit 19.1 ESSA PHARMA INC. DISCLOSURE AND INSIDER TRADING POLICY Amended on June, 2023 Throughout this document, “ESSA,” the “Company,” and the “Corporation” refer to ESSA Pharma Inc. and all of its consolidated subsidiaries and affiliates, including ESSA Pharmaceuticals Corp. A. OBJECTIVE AND SCOPE 1. The objective of this disclosure policy (this “Policy”) is to ensure that those who come into |
|
| December 17, 2024 |
ESSA Pharma Inc. Severance Plan Exhibit 10.13 ESSA PHARMA INC. SEVERANCE PLAN Section 1.Purpose of the Plan This ESSA Pharma Inc. Severance Plan (the “Plan”) is intended to promote the interests of the Company by helping the Company retain qualified executives, maintain a stable work environment and provide economic security to eligible executives in the event of certain qualifying terminations of employment, including in connec |
|
| December 17, 2024 |
The ESSA Pharma Inc. Clawback Policy Exhibit 97 ESSA PHARMA INC. CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of ESSA Pharma Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. 1. Definitions For pur |
|
| December 17, 2024 |
Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT This Amendment to the Amended and Restated License Agreement (the “Amendment”) is entered into and effective as of May 25, 2021 by and between BC CANCER, part of the Provincial Health Services Authority amalgamated under the Society Act (British Columbia), having an office at Suite 600, West 10th Avenue, Vancouver, British Colu |
|
| December 17, 2024 |
Exhibit 21.1 List of Subsidiaries Name Abbreviation Place of Incorporation ESSA Pharmaceuticals Corp. ESSA Texas State of Texas |
|
| December 16, 2024 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| December 6, 2024 |
ESSA PHARMA INC. SEVERANCE PLAN Exhibit 99.1 ESSA PHARMA INC. SEVERANCE PLAN Section 1. Purpose of the Plan This ESSA Pharma Inc. Severance Plan (the “Plan”) is intended to promote the interests of the Company by helping the Company retain qualified executives, maintain a stable work environment and provide economic security to eligible executives in the event of certain qualifying terminations of employment, including in connec |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission File |
|
| November 14, 2024 |
EPIX / ESSA Pharma Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3)* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 29668H708 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing |
|
| November 14, 2024 |
EPIX / ESSA Pharma Inc. / RTW INVESTMENTS, LP Passive Investment SC 13G/A 1 p24-3274sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 29668H708 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the |
|
| November 14, 2024 |
EPIX / ESSA Pharma Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d854164dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) November 1, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate th |
|
| November 8, 2024 |
EPIX / ESSA Pharma Inc. / TANG CAPITAL MANAGEMENT LLC Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no. |
|
| November 7, 2024 |
EPIX / ESSA Pharma Inc. / BML Investment Partners, L.P. Passive Investment SC 13G 1 epix13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 2966H708 (CUSIP Number) Novembe |
|
| November 1, 2024 |
Exhibit 99.1 ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Efficacy signals observed will not achieve ESSA’s target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a |
|
| November 1, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commissio |
|
| September 16, 2024 |
Exhibit 99.1 ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fi |
|
| August 5, 2024 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 P |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-3 |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - - - - - - - - - FORM 8-K - - - - - - - - - CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2024 - - - - - - - - - ESSA Pharma Inc. (Exact name of registrant as specified in its charter) - - - - - - - - - British Columbia, Canada ( |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001- |
|
| May 14, 2024 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achie |
|
| April 5, 2024 |
As filed with the Securities and Exchange Commission on April 5, 2024 As filed with the Securities and Exchange Commission on April 5, 2024 Registration No. |
|
| April 5, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ESSA PHARMA INC. |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| February 14, 2024 |
EPIX / ESSA Pharma Inc. / RTW INVESTMENTS, LP - ESSA PHARMA INC. Passive Investment SC 13G 1 p24-0731sc13g.htm ESSA PHARMA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 2966H708 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to desig |
|
| February 14, 2024 |
EPIX / ESSA Pharma Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm245198d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2 |
|
| February 13, 2024 |
EPIX / ESSA Pharma Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d749789dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| February 13, 2024 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63 |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 0 |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 - - - - - - - - - FORM 8-K - - - - - - - - - CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2024 - - - - - - - - - ESSA Pharma Inc. (Exact name of registrant as specified in its charter) - - - - - - - - - British Columbia, Can |
|
| January 29, 2024 |
Exhibit 99.1 ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD |
|
| January 29, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2024 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| January 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| January 23, 2024 |
EPIX / ESSA Pharma Inc. / Soleus Capital, LLC - AMENDMENT NO. 6 Passive Investment SC 13G/A 1 schedule13ga.htm AMENDMENT NO. 6 CUSIP No. 29668H708 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| December 12, 2023 |
Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT This Amendment to the Amended and Restated License Agreement (the “Amendment”) is entered into and effective as of May 25, 2021 by and between BC CANCER, part of the Provincial Health Services Authority amalgamated under the Society Act (British Columbia), having an office at Suite 600, West 10th Avenue, Vancouver, British Colu |
|
| December 12, 2023 |
Exhibit 21.1 List of Subsidiaries Name Abbreviation Place of Incorporation ESSA Pharmaceuticals Corp. ESSA Texas State of Texas |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-37410 ESSA Pharma Inc. |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| December 12, 2023 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023 Head-to-head Phase 2 dose expan |
|
| December 12, 2023 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of ESSA Pharma Inc. (the “Company,” “our” and “we”) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company’s Articles of Incorporation, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit |
|
| December 12, 2023 |
The ESSA Pharma Inc. Clawback Policy Exhibit 97 ESSA PHARMA INC. CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of ESSA Pharma Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. 1. Definitions For pur |
|
| November 6, 2023 |
Exhibit 1.1 Execution Version OPEN MARKET SALE AGREEMENTSM November 3, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ESSA Pharma Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent |
|
| November 6, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| November 6, 2023 |
ESSA PHARMA INC. Up to $50,000,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-274584 PROSPECTUS SUPPLEMENT (To prospectus dated October 10, 2023) ESSA PHARMA INC. Up to $50,000,000 Common Shares We have entered into an Open Market Sale AgreementSM, or Sales Agreement, with Jefferies LLC, or Jefferies, dated November 3, 2023, relating to the sale of our common shares from time to time offered by this prospectus supplement |
|
| November 6, 2023 |
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement Exhibit 99.1 ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov 6, 2023 – ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM |
|
| October 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| October 27, 2023 |
Exhibit 99.1 ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently enrolled into cohort four, 81% of patients achieved P |
|
| October 23, 2023 |
EXHIBIT 99.1 ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently enrolled into cohort four, 69% of patients achieved PSA90, 6 |
|
| October 23, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| October 6, 2023 |
October 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 6, 2023 |
October 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| October 3, 2023 |
New York, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 Skadden, Arps, Slate, Meagher & Flom llp One Manhattan West New York, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 www. |
|
| October 3, 2023 |
As Filed with the Securities and Exchange Commission on October 3, 2023 As Filed with the Securities and Exchange Commission on October 3, 2023 Registration No. |
|
| September 19, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) ESSA PHARMA INC. |
|
| September 19, 2023 |
As Filed with the Securities and Exchange Commission on September 19, 2023 As Filed with the Securities and Exchange Commission on September 19, 2023 Registration No. |
|
| September 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commissio |
|
| September 18, 2023 |
EXHIBIT 99.1 ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1 results |
|
| September 18, 2023 |
Exhibit 3.1 ARTICLES ESSA PHARMA INC. (the “Company”) The Company has as its Articles the following Articles. Full Name and Signature of Each Incorporator Date of Signing FMC VANCOUVER SERVICES INC. Gary R. Sollis, Authorized Signatory Incorporation Number: TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Statutory Definitions Applicable 1 ARTICLE 2 SHARES AND SHARE CERTIFICATES |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commissio |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-3 |
|
| August 8, 2023 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Entered into clinical trial support agreement with Janssen to supply Erleada® ( |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————————— FORM 8-K ————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 ————————— ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ————————— British Columbia, Canada (State or other jurisdiction of |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission File |
|
| June 6, 2023 |
ESSA Pharma Appoints Lauren Merendino to its Board of Directors Exhibit 99.1 ESSA Pharma Appoints Lauren Merendino to its Board of Directors South San Francisco, California and Vancouver, Canada, June 6, 2023 - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of |
|
| May 9, 2023 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Continue to enroll patients into the fo |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001- |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission File |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 12, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fi |
|
| April 12, 2023 |
EXHIBIT 99.1 ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer South San Francisco, California and Vancouver, Canada, April 12, 2023 - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, toda |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————————— FORM 8-K ————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2023 ————————— ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ————————— British Columbia, Canada (State or other jurisdiction of |
|
| February 14, 2023 |
EPIX / ESSA Pharma Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d5sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 20 |
|
| February 14, 2023 |
EPIX / ESSA Pharma Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Essa Pharma Inc. (Name of Issuer – as specified in its charter) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2023 |
EPIX / ESSA Pharma Inc / RTW INVESTMENTS, LP - ESSA PHARMA INC. Passive Investment SC 13G/A 1 p23-0693sc13ga.htm ESSA PHARMA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box t |
|
| February 14, 2023 |
EX-99.B 2 d406969dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
EPIX / ESSA Pharma Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d979868413g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2023 |
EPIX / ESSA Pharma Inc / Soleus Capital, LLC - AMENDMENT NO. 5 Passive Investment SC 13G/A 1 schedule13ga.htm AMENDMENT NO. 5 CUSIP No. 29668H708 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 14, 2023 |
EPIX / ESSA Pharma Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d406969dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 0 |
|
| February 7, 2023 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing South San Francisco, California and Vancouver, Canada, Fe |
|
| February 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 7, 2023 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| January 24, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| December 13, 2022 |
Exhibit 21.1 ? List of Subsidiaries ? ? ? ? ? ? Name Abbreviation Place of Incorporation ESSA Pharmaceuticals Corp. ESSA Texas State of Texas ? ? ? ? ? ? ? ? ? ? ? |
|
| December 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2022 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| December 13, 2022 |
Exhibit 4.2 ? DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of ESSA Pharma Inc. (the ?Company,? ?our? and ?we?) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company?s Articles of Incorporation, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibi |
|
| December 13, 2022 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 South San Francisco, California and Vancouver, Canada, December 13, 2022 - ESSA Pharma Inc. (?ESSA?, or the ?Company?) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today pr |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-37410 ESSA Pharma Inc. |
|
| November 10, 2022 |
EPIX / ESSA Pharma Inc / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* ESSA Pharma, Inc. (Name of Issuer) Common stock, no par value (Title of Class of Securities) 29668H708 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of the State |
|
| November 10, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of ESSA Pharma, Inc., a corporation organized under the laws of British Columbia, Canada, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2022 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| October 31, 2022 |
ESSA Provides an Update on its Clinical Collaboration with Janssen Exhibit 99.1 ESSA Provides an Update on its Clinical Collaboration with Janssen South San Francisco, California and Vancouver, Canada, October 31, 2022 - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Janssen Research and Development (“Janssen”) is s |
|
| October 27, 2022 |
EPIX / ESSA Pharma Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2022 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| October 26, 2022 |
Exhibit 99.1 Updated Results from the Phase 1/2 Study of ESSA’s Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen (“PSA”) reductions observ |
|
| September 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2022 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commissio |
|
| September 13, 2022 |
ESSA Pharma Appoints Philip Kantoff to its Board of Directors Exhibit 99.1 ESSA Pharma Appoints Philip Kantoff to its Board of Directors South San Francisco, California and Vancouver, Canada, September 13, 2022 - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of |
|
| August 4, 2022 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 South San Francisco, California and Vancouver, Canada, August 4, 2022 - ESSA Pharma Inc. (?ESSA?, or the ?Company?) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ????????? FORM 8-K ????????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 ????????? ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ????????? British Columbia, Canada (State or other jurisdiction of |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 ESSA Pharma Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 29668H708 (CUSIP Number) July 8, 2022 (D |
|
| June 27, 2022 |
Exhibit 99.1 ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 27, 2022 |
|
| June 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ????????? FORM 8-K ????????? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2022 ????????? ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ????????? British Columbia, Canada (State or other jurisdiction of |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission File |
|
| May 10, 2022 |
Exhibit 99.1 999 West Broadway, Suite 720, Vancouver, BC, V5Z 1K5 T. 778.331.0962 | essapharma.com ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 South San Francisco, California and Vancouver, Canada, May 10, 2022 - ESSA Pharma Inc. (?ESSA?, or the ?Company?) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2022 |
ESSA PHARMA INC. 2022 OMNIBUS INCENTIVE PLAN Exhibit 99.1 ESSA PHARMA INC. 2022 OMNIBUS INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the ESSA Pharma Inc. 2022 Omnibus Incentive Plan (the ?Plan?). The purposes of the Plan are to provide an additional incentive to selected officers, employees, non-employee directors and consultants of the Company or its Affiliates whose contributions are essential to the growth and succes |
|
| March 10, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2022 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fil |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 ESSA Pharma Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 20 |
|
| February 14, 2022 |
EPIX / ESSA Pharma Inc / RTW INVESTMENTS, LP - ESSA PHARMA INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 14, 2022 |
EPIX / ESSA Pharma Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* ESSA Pharma Inc. (Name of Issuer ? as specified in its charter) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 11, 2022 |
EPIX / ESSA Pharma Inc / Vivo Capital IX, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 11, 2022 |
EPIX / ESSA Pharma Inc / PFIZER INC - SC 13G/A ESSA PHARMA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2021 (Da |
|
| February 11, 2022 |
EPIX / ESSA Pharma Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 10, 2022 |
EPIX / ESSA Pharma Inc / Soleus Capital, LLC - AMENDMENT NO. 4 Passive Investment CUSIP No. 29668H104 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| January 12, 2022 |
EPIX / ESSA Pharma Inc / Clarus Lifesciences III, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ESSA PHARMA INC. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H104 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, Suite 1210 Cambridge, MA 02142 Tel: (617) 949-2200 (Name, Address and Telephone Number of Person A |
|
| November 18, 2021 |
Exhibit 4.2 ? DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of ESSA Pharma Inc. (the ?Company,? ?our? and ?we?) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company?s Articles of Incorporation, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibi |
|
| November 18, 2021 |
Exhibit 21.1 ? List of Subsidiaries ? ? ? ? ? ? Name Abbreviation Place of Incorporation ESSA Pharmaceuticals Corp. ESSA Texas State of Texas Realm Therapeutics, plc Realm United Kingdom Realm Therapeutics, Inc. Realm USA State of Delaware ? |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ?ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-37410 ? ESSA Pharm |
|
| October 1, 2021 |
As filed with the Securities and Exchange Commission on October 1, 2021 As filed with the Securities and Exchange Commission on October 1, 2021 Registration No. |
|
| August 23, 2021 |
EPIX / ESSA Pharma Inc / DRIEHAUS CAPITAL MANAGEMENT LLC - NONE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc (Name of Issuer) Common Stock (Title of Class of Securities) 29668H708 (CUSIP Number) August 16, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| August 17, 2021 |
EPIX / ESSA Pharma Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) August 16, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 2, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, no par value of ESSA Pharma Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further |
|
| July 2, 2021 |
EPIX / ESSA Pharma Inc / RTW INVESTMENTS, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 21, 2021 |
As Filed with the Securities and Exchange Commission on June 21, 2021 As Filed with the Securities and Exchange Commission on June 21, 2021 Registration No. |
|
| May 6, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 5, 2021 |
SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) April 29, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Ru |
|
| March 31, 2021 |
ESSA Announces Change to its Board of Directors Exhibit 99.1 ESSA Announces Change to its Board of Directors Houston, Texas and Vancouver, Canada, March 26, 2021 - ESSA Pharma Inc. (“ESSA” or the “Company”) (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Ari Brettman, M.D., has stepped down from ESSA’s Board of Directors, which he has been a |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2021 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission Fi |
|
| March 2, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2021 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| February 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2021 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| February 22, 2021 |
Underwriting Agreement, dated February 17, 2021 Exhibit 1.1 4,830,918 Shares ESSA Pharma Inc. UNDERWRITING AGREEMENT February 17, 2021 JEFFERIES LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Introductory. ESSA Pharma Inc., a company incorporated un |
|
| February 18, 2021 |
ESSA PHARMA INC. 4,830,918 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-250971 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED DECEMBER 29, 2020) ESSA PHARMA INC. 4,830,918 Common Shares We are offering 4,830,918 common shares pursuant to this prospectus supplement and the accompanying prospectus. Our common shares are listed on the Nasdaq Capital Market (the “Nasdaq”) under the symbol “EPIX.” On February 12, 2021, th |
|
| February 16, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* ESSA Pharma Inc (Name of Issuer) Common Stock (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 16, 2021 |
Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* ESSA Pharma Inc (Name of Issuer) Common Stock (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 16, 2021 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020 Vancouver, Canada and Houston, Texas, February 11, 2021 - ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update an |
|
| February 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2021 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada (State or other jurisdiction of incorporation) 001-37410 (Commission |
|
| February 16, 2021 |
$100,000,000 ESSA PHARMA INC. Common Shares This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Essa Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 12, 2021 |
CUSIP No. 29668H104 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESSA Pharma Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 29668H104 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 12, 2021 |
EX-99.2 CUSIP No. 29668H104 13G Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person’s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the “Rep |
|
| February 12, 2021 |
EX-99.1 CUSIP No. 29668H104 13G Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Essa Pharma Inc. Dated: February 12, 2021 OMEGA FUND IV, L.P. BY: |
|
| February 12, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Essa Pharma Inc. (Name of Issuer) Shares of Common Stock (Title of Class of Securities) 29668H104 (CUSIP Number) December 31, 2020 (Date of Event |
|
| February 11, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 0 |
|
| February 11, 2021 |
EX-99.1 Exhibit 99.1 ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium Vancouver, Canada and Houston, Texas, February 11, 2021 - ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the tr |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 ESSA Pharma Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 29668H708 (CUSIP Number) December 31, 20 |
|
| February 11, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2021 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37410 47-2569713 (State or other jurisdiction of incorporation) |
|
| January 26, 2021 |
Definitive Proxy Statement on Schedule 14A, dated January 26, 2021 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ |
|
| January 19, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| December 23, 2020 |
December 23, 2020 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 23, 2020 |
CORRESP 1 filename1.htm December 23, 2020 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: ESSA Pharma Inc. Registration Statement on Form S-3 Ladies and Gentlemen: On behalf of ESSA Pharma Inc. (the “Company”), we respectfully request that the U.S. Securities and Exchange Commission take appropriate action to ac |
|
| December 23, 2020 |
December 23, 2020 Via EDGAR Alan Campbell Mary Beth Breslin Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N. |
|
| December 23, 2020 |
December 23, 2020 Via EDGAR Alan Campbell Mary Beth Breslin Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N. |
|
| December 23, 2020 |
As Filed with the Securities and Exchange Commission on December 23, 2020 Registration No. |
|
| December 23, 2020 |
As Filed with the Securities and Exchange Commission on December 23, 2020 Registration No. |
|
| December 15, 2020 |
Exhibit 99.3 ESSA PHARMA INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Expressed in United States dollars) (Unaudited) FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2020 The accompanying unaudited condensed consolidated interim financial statements do not include all information and footnotes required for a complete set of annual financial statements prepared in accordance with United S |
|
| December 15, 2020 |
Exhibit 99.2 ESSA PHARMA INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Expressed in United States dollars) (Unaudited) FOR THE THREE MONTHS ENDED DECEMBER 31, 2019 The accompanying unaudited condensed consolidated interim financial statements do not include all information and footnotes required for a complete set of annual financial statements prepared in accordance with United States |
|
| December 15, 2020 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of ESSA Pharma Inc. (the “Company,” “our” and “we”) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Company’s Articles of Incorporation, which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit |
|
| December 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: December 15, 2020 Commission file number: 001-37410 ESSA Pharma Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 47-2569713 (State or other jurisdiction of (I.R.S. Employer incorporation or organi |
|
| December 15, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-3741 |
|
| December 15, 2020 |
Exhibit 99.4 ESSA PHARMA INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Expressed in United States dollars) (Unaudited) FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2020 The accompanying unaudited condensed consolidated interim financial statements do not include all information and footnotes required for a complete set of annual financial statements prepared in accordance with United S |
|
| December 15, 2020 |
Exhibit 21.1 List of Subsidiaries Name Abbreviation Place of Incorporation ESSA Pharmaceuticals Corp. ESSA Texas State of Texas Realm Therapeutics, plc Realm United Kingdom Realm Therapeutics, Inc. Realm USA State of Delaware |
|
| December 15, 2020 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2020 Vancouver, Canada and Houston, Texas, December 15, 2020 - ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporat |
|
| November 25, 2020 |
As Filed with the Securities and Exchange Commission on November 25, 2020 Registration No. |
|
| November 25, 2020 |
As Filed with the Securities and Exchange Commission on November 25, 2020 Registration No. |
|
| November 6, 2020 |
EPIX / ESSA Pharma Inc. / Vivo Capital IX, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ESSA Pharma Inc. (Name of Issuer) Common Stock, without par value (Title of Class of Securities) 29668H104 (CUSIP Number) October 29, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| October 27, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ————————— FORM 8-K ————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2020 ————————— ESSA Pharma Inc. (Exact name of registrant as specified in its charter) ————————— British Columbia, Canada (State or other jurisdiction |
|
| October 27, 2020 |
ESSA Pharma Inc. Announces Delisting from the TSX-V Exhibit 99.1 ESSA Pharma Inc. Announces Delisting from the TSX-V HOUSTON and VANCOUVER, BC, Oct. 26, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today its intention to voluntarily delist all of its issued and outstanding common share |
|
| September 21, 2020 |
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit Exhibit 99.1 ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Oppenheimer |
|
| September 21, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal |
|
| September 17, 2020 |
Exhibit 99.1 ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020 HOUSTON and VANCOUVER, BC, Sept. 17, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of data of ESSA's clinica |
|
| September 17, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal |
|
| September 14, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal |
|
| September 14, 2020 |
Exhibit 99.1 ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer HOUSTON and VANCOUVER, BC, Sept. 14, 2020 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX) (TSXV: EPI) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer today |
|
| September 10, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal |
|
| September 10, 2020 |
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences Exhibit 99.1 ESSA Pharma to Participate in Multiple Upcoming Investor Conferences HOUSTON and VANCOUVER, BC, Sept. 10, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 22nd Annual Glob |
|
| August 19, 2020 |
EPIX / ESSA Pharma Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 19, 2020 |
CUSIP No 29668H104 SCHEDULE 13G Page 7 of 7 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated August 19, 2020 (the “Schedule 13G”), with respect to the Common Stock of Essa Pharma Inc. |
|
| August 13, 2020 |
As filed with the Securities and Exchange Commission on August 12, 2020 Registration No. |
|
| August 7, 2020 |
FORM 51-102F1 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED JUNE 30, 2020 AND 2019 Exhibit 99.3 FORM 51-102F1 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED JUNE 30, 2020 AND 2019 ESSA Pharma Inc. 900 West Broadway, Suite 720 Vancouver, BC V5Z 1K5 Canada ESSA Pharmaceuticals Corp. 700 Milam St., Suite 1300 Houston, TX 77002 USA Management’s Discussion and Analysis June 30, 2020 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
|
| August 7, 2020 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.5 Form 52-109F2 Certification of Interim Filings Full Certificate I, David Wood, Chief Financial Officer of ESSA Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ESSA Pharma Inc. (the “issuer”) for the interim period ended June 30, 2020. 2. No misrepresentations: Based on my knowledge, havin |
|
| August 7, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal exe |
|
| August 7, 2020 |
Exhibit 99.1 ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020 VANCOUVER, BC and HOUSTON, Aug. 6, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and |
|
| August 7, 2020 |
Exhibit 99.2 CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited) (Expressed in United States dollars) FOR THE NINE MONTHS ENDED JUNE 30, 2020 AND 2019 ESSA PHARMA INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (Unaudited) (Expressed in United States dollars) AS AT June 30, 2020 September 30, 2019 ASSETS Current Cash and cash equivalents $ 36,482,049 $ 53,322,723 R |
|
| August 7, 2020 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, David R. Parkinson, Chief Executive Officer of ESSA Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of ESSA Pharma Inc. (the “issuer”) for the interim period ended June 30, 2020. 2. No misrepresentations: Based on my knowledg |
|
| August 6, 2020 |
7,100,000 Shares ESSA Pharma Inc. UNDERWRITING AGREEMENT Exhibit 99.1 7,100,000 Shares ESSA Pharma Inc. UNDERWRITING AGREEMENT July 28, 2020 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. ESSA Pharma Inc., a company incorporated under the laws of the Province of British Columbia (the “Company”), proposes to issue and sell to the several underwr |
|
| August 6, 2020 |
EPIX / ESSA Pharma Inc. / PFIZER INC - SC 13G ESSA PHARMA INC. Passive Investment CUSIP No. 29668H708 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 ESSA Pharma Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 29668H708 (CUSIP Number) July 31, 2020 (D |
|
| August 6, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal exe |
|
| August 3, 2020 |
EPIX / ESSA Pharma Inc. / Soleus Capital, Llc - AMENDMENT NO. 2 Passive Investment CUSIP No. 29668H104 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ESSA Pharma Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 29668H104 (CUSIP Number) July 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| July 31, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal execu |
|
| July 31, 2020 |
ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 Exhibit 99.1 ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000 HOUSTON and VANCOUVER, BC, July 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritten public offering of |
|
| July 30, 2020 |
ESSA PHARMA INC. 7,100,000 Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-225969 PROSPECTUS SUPPLEMENT (To prospectus dated July 17, 2018) ESSA PHARMA INC. 7,100,000 Common Shares We are offering 7,100,000 common shares pursuant to this prospectus supplement and the accompanying prospectus. Our common shares are listed on the Nasdaq Capital Market (the “Nasdaq”) under the symbol “EPIX” and on the |
|
| July 29, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal execu |
|
| July 29, 2020 |
ESSA Pharma Announces Pricing of Public Offering of Common Shares Exhibit 99.1 ESSA Pharma Announces Pricing of Public Offering of Common Shares VANCOUVER, BC and HOUSTON, July 28, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 7,100,000 common |
|
| July 28, 2020 |
ESSA Pharma Announces Proposed Public Offering of Common Shares Exhibit 99.1 ESSA Pharma Announces Proposed Public Offering of Common Shares VANCOUVER, BC and HOUSTON, July 28, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has commenced an underwritten public offering of its common sh |
|
| July 28, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal execu |
|
| July 28, 2020 |
ESSA PHARMA INC. Common Shares TABLE OF CONTENTS This preliminary prospectus supplement and the accompanying prospectus relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 15, 2020 |
Exhibit 99.1 ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer HOUSTON and VANCOUVER, BC, July 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in |
|
| July 15, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal execu |
|
| June 30, 2020 |
As filed with the Securities and Exchange Commission on June 29, 2020 Registration No. |
|
| June 22, 2020 |
Exhibit 99.1 ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II HOUSTON and VANCOUVER, BC, June 22, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX); (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ES |
|
| June 22, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal execu |
|
| May 27, 2020 |
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference Exhibit 99.1 ESSA Pharma to Present at Jefferies Virtual Healthcare Conference HOUSTON and VANCOUVER, May 27, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Jefferies Virtual Healthcare Conference o |
|
| May 27, 2020 |
Current Report of Foreign Issuer - FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2020 Commission File Number 001-37410 ESSA Pharma Inc. (Translation of registrant’s name into English) Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 (Address of principal execut |
